Table 1.
Patient characteristics.
| IA before alloSCT |
Total (N = 1439) | p Value | ||
|---|---|---|---|---|
| No (N = 1352) | Yes (N = 87) | |||
| Age at alloSCT Median (min—max) | 41.0 (0.4–75.8) | 45.4 (1.7–68.0) | 41.0 (0.4–75.8) | 0.9 |
| Children <18 years old | 420 (31.1) | 29 (33.3) | 449 (31.2) | |
| Adults | 932 (68.9) | 58 (66.7) | 990 (68.8) | |
| Underlying malignancy | 0.8 | |||
| ALL | 434 (32.1) | 29 (33.3) | 463 (32.2) | |
| AML | 918 (67.9) | 58 (66.7) | 976 (67.8) | |
| Interval from leukaemia diagnosis to alloSCT (months) Median (min—max) | 6.9 (0.3–267.8) | 6.3 (2.2–165.3) | 6.9 (0.3–267.8) | 0.5 |
| Acute leukaemia status before alloSCT | 0.1 | |||
| CR | 1052 (77.8) | 74 (85.1) | 1126 (78.2) | |
| Other | 300 (22.2) | 13 (14.9) | 313 (21.8) | |
| Donor type | 0.004 | |||
| HLA-identical sibling | 347 (25.7) | 36 (41.4) | 383 (26.6) | |
| Haplo | 223 (16.5) | 14 (16.1) | 237 (16.5) | |
| Unrelated donor | 782 (57.8) | 37 (42.5) | 819 (56.9) | |
| Stem cell source | 0.5 | |||
| Bone marrow | 351 (26.0) | 18 (20.7) | 369 (25.6) | |
| Peripheral blood | 964 (71.3) | 67 (77.0) | 1031 (71.6) | |
| Cord blood | 37 (2.7) | 2 (2.3) | 39 (2.7) | |
| Conditioning regimen | 0.051 | |||
| Myeloablative | 1026 (75.9) | 74 (85.1) | 1100 (76.4) | |
| Reduced | 326 (24.1) | 13 (14.9) | 339 (23.6) | |
| Total body irradiation | 0.6 | |||
| No | 935 (69.2) | 58 (66.7) | 993 (69.0) | |
| Yes | 417 (30.8) | 29 (33.3) | 446 (31.0) | |
| In-vivo T-cell depletion (ATG or Campath) | 0.5 | |||
| No | 682 (50.4) | 47 (54.0) | 729 (50.7) | |
| Yes | 670 (49.6) | 40 (46.0) | 710 (49.3) | |